A new oral medication could reshape how millions of people with type 2 diabetes manage their condition, offering the blood sugar control and weight loss benefits of GLP-1 drugs without requiring injections or strict dosing routines.
The experimental pill, elecoglipron, delivered striking results in a late-stage clinical trial. Nearly 90 percent of patients who took the highest doses achieved target blood glucose levels, compared to just 25 percent on placebo. The weight loss effect was equally impressive: 72 percent of those on the medication lost at least 5 percent of body weight, versus 20 percent in the placebo group.
Researchers at Mass General Brigham presented the findings from the SOLSTICE trial at the American Diabetes Association's Scientific Sessions, with results simultaneously published in The Lancet. The trial enrolled 406 adults across nine countries and tested different doses and escalation schedules to identify the most effective approach.
The breakthrough matters because current GLP-1 treatments carry real friction. Most require weekly or daily injections. Semaglutide, the lone approved oral GLP-1 option for diabetes, demands an empty stomach, no food or water for 30 minutes after taking it, and must be swallowed first thing in the morning. These constraints matter in real life, where adherence problems often derail treatment.
Elecoglipron was purpose-built to address those limitations. As an oral non-peptide GLP-1 receptor agonist, it belongs to a newer class designed for easier administration without the absorption complications that plague larger peptide molecules.
The drug's safety profile tracked with other GLP-1 therapies in development, according to researchers. Side effects, though not detailed in the trial summary, proved manageable enough to sustain high completion rates across all dose groups.
Dr. Vanita Aroda, who led the trial and directs diabetes clinical research at Mass General Brigham, emphasized that rigorous trials like SOLSTICE unlock real progress. "To date, GLP-1 therapies have largely been limited to injectable or oral peptide formulations, each with inherent delivery and dosing constraints," she said, noting that new oral medications could offer comparable effectiveness without those barriers.
The work builds on a broader research push to expand GLP-1 options. Aroda is also principal investigator for REIMAGINE 1, testing CagriSema, a combination of cagrilintide and semaglutide, which similarly showed strong results with 87 percent of participants hitting blood glucose targets.
AstraZeneca funded and sponsored the SOLSTICE trial. The company has invested heavily in expanding its GLP-1 portfolio as demand surges for these drugs beyond diabetes into weight management and cardiovascular protection.
Elecoglipron still faces the typical path to FDA approval, meaning patients won't access it immediately. But the trial data suggest that the next generation of GLP-1 treatments could strip away the friction that complicates access and adherence today. For a disease affecting over 37 million Americans, simpler, equally effective options could be transformative.
Author Jessica Williams: "These results suggest the real competition in diabetes care is shifting from drug to drug toward drug form: if a pill works as well as a shot, the pill wins on compliance alone."
Comments